Department of Rheumatology, Ankara City Hospital, Ankara, Turkey.
Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
J Infect Dev Ctries. 2022 Jan 31;16(1):57-62. doi: 10.3855/jidc.14924.
Colchicine is an ancient agent with well-known anti-inflammatory effects and commonly used in treatment of hyperinflammatory conditions. It has been argued that colchicine could be an appropriate treatment option in COVID-19 to control hyperinflammatory response. Here in this study, we aimed to investigate the impact of colchicine on outcomes of COVID-19 in our inpatient cohort.
In this retrospective cohort study, hospitalized COVID-19 patients were investigated. Demographics, comorbidities, COVID-19 symptoms, laboratory findings on admission and discharge, baseline and seventh day oxygenation status, rates of mortality, intensive care unit admission, administration of other anti-inflammatory treatments and length of hospital stay were compared between patients who received standard of care medications and who received colchicine additionally.
Three hundred and thirty-six patients were included in the study (171 standard of care, 165 standard of care plus colchicine). The median length of hospital stay in colchicine group was significantly shorter. Rates of admission to intensive care unit, anti-inflammatory treatment administration and mortality did not differentiate between standard of care and colchicine groups. However, reduced rates of mortality and ICU admission were observed in patients who received colchicine with a dose of 1 mg/day when compared to patients who received 0.5 mg/day.
Our study demonstrated that COVID-19 patients who received colchicine in addition to standard of care had shorter hospital stay. Our results further support the use of colchicine in treatment of COVID-19, particularly with a dose of 1 mg/day.
秋水仙碱是一种具有显著抗炎作用的古老药物，常用于治疗炎症反应过高的疾病。有人认为，秋水仙碱可能是治疗 COVID-19 的一种合适选择，可以控制过度的炎症反应。在这项研究中，我们旨在调查秋水仙碱对我们住院患者队列中 COVID-19 结局的影响。
这是一项回顾性队列研究，调查了住院的 COVID-19 患者。比较了接受标准治疗药物和同时接受秋水仙碱治疗的患者之间的人口统计学特征、合并症、COVID-19 症状、入院和出院时的实验室检查结果、基线和第 7 天的氧合状态、死亡率、重症监护病房入院率、其他抗炎治疗的应用以及住院时间。
本研究共纳入 336 例患者（标准治疗组 171 例，标准治疗加秋水仙碱组 165 例）。秋水仙碱组的住院时间中位数明显更短。重症监护病房入院率、抗炎治疗应用率和死亡率在标准治疗组和秋水仙碱组之间没有差异。然而，与接受 0.5mg/天秋水仙碱的患者相比，接受 1mg/天秋水仙碱的患者死亡率和重症监护病房入院率降低。
我们的研究表明，除标准治疗外，还接受秋水仙碱治疗的 COVID-19 患者住院时间更短。我们的结果进一步支持在 COVID-19 治疗中使用秋水仙碱，特别是使用 1mg/天的剂量。
